Video

Data Diversity Initiative: Tackling the Medical Research Data Gap

The data-gap in medical research is well documented, and has serious implications for large sections of the world’s population.

Diseases, treatments and drugs affect people differently according to factors such as race, ethnicity, gender or age, meaning these data gaps in research drastically limit our knowledge to effectively diagnose and treat disease. In the age of digital health, the data-gap can no longer be overlooked if we are to avoid exacerbating existing health inequalities.  

At BenevolentAI, we launched an internal initiative to address this challenge, raise awareness and brainstorm possible solutions to the data diversity problem. We then broadened our scope by engaging with the wider scientific and research community.  

During our inaugural event, we invited a panel of experts to discuss the problem of diversity in medical data, and then invited our audience to participate in an interactive workshop to brainstorm holistic and concrete solutions:  

  • Maria Nelson, Senior Head of Innovation Practice, Digital Catapult  
  • Jackie Hunter, CE Clinical and Strategic Partnerships BenevolentAI  
  • Rob Wilson, Senior Regulatory Consultant, DLRC  
  • Diane Harbison, CEO Decipher Analytics  
  • Dawn Duhaney, Product Manager, Wellcome Trust


More Posts

You Might Also Like

Blog
Tech Nation Visa: the gateway to world-leading UK tech jobs
Drawing attention to the Tech Nation Visa, a great initiative that enables the brightest international talent to live and work in the UK.
Feb 19, 2021
News
BenevolentAI announces first patient dosed in its Atopic Dermatitis clinical trial
A molecule designed and developed by BenevolentAI to treat mild to moderate Atopic Dermatitis has entered clinical trials.
Feb 11, 2021
News
BenevolentAI and AstraZeneca achieve collaboration milestone with novel AI-generated chronic kidney disease target
BenevolentAI and AstraZeneca hit collaboration milestone with an AI-generated CKD target from the partnership entering AstraZeneca’s portfolio.
Jan 27, 2021
News
ACTT-2 trial results published in the New England Journal of Medicine validate baricitinib’s efficacy in combination with remdesivir in hospitalised COVID-19 patients
Peer-reviewed data from the ACTT-2 further validate BenevolentAI’s hypothesis for baricitinib as a potential COVID-19 treatment.
Jan 15, 2021
Blog
Joanna Shields speaks at the Global Partnership on Artificial Intelligence
BenevolentAI CEO Joanna Shields opened the final plenary of the Global Partnership on Artificial Intelligence (GPAI) summit with a powerful message on the future of AI.
Dec 11, 2020
Blog
BenevolentAI wins Innovation Award at 2020 Scrip Awards
BenevolentAI wins the Innovation Award at the prestigious 2020 Scrip Awards for our work in artificial intelligence applied drug discovery.
Dec 11, 2020